SYDNEY, Australia, 23 May 2019 – Vitex Pharmaceuticals Chief Executive Officer, Dr Aniss Chami, has been awarded the 2019 Corporate Citizen of the Year award by Blacktown City Council.
Dr Chami was presented with his award during a successful ‘2019 Budget Insight for Business’ forum on Tuesday 22 May by Blacktown City Mayor Stephen Bali MP. The forum provided an opportunity for almost 90 business representatives to receive a detailed briefing on Blacktown City Council’s record $736 million balanced budget and progress in Council’s plans to transform Blacktown.
“We are proud to recognise Dr Aniss Chami as our Corporate Citizen of the Year,” said Blacktown City Mayor Stephen Bali MP.
“With a remarkable list of credentials, Dr Chami is one of the youngest CEOs in the industry. He has achieved international success in the industry and at the same time demonstrated a high level of community involvement within Blacktown City,” continued Mayor Bali.
“Dr Chami is also known for his philanthropic work, particularly with the Antiochian Orthodox Church and in helping migrants when they first arrive in Australia. He is passionate about Australian-made products and has an international reputation for innovative quality systems underscored by an entrepreneurial spirit,” concluded Mayor Bali.
Dr Chami graduated from Macquarie University completing his Bachelor of Medical Science with Honours (B Med Sci) (Hon). He went on to complete his Master of Pharmacy (MPharm) at the University of Sydney, before completing his Bachelor of Medicine and Bachelor of Surgery (MBBS) at the prestigious Sydney School of Medicine, University of Notre Dame. Dr Chami also holds a Master’s Degree in Financial Management (MFM) and a Master’s Degree in Business Administration (MBA) at the world-ranking Macquarie Graduate School of Management.
Dr Chami is currently a prominent member of the industry’s representative association the Complementary Medicines Association of Australia (CMA) and is the Chair of the Good Manufacturing Practice (GMP) Manufacturing and Quality Committee which liaises directly with the federal regulator of medicines manufacture, the Therapeutic Goods Administration (TGA), on issues pertaining to quality, compliance and manufacturing standards.